SC
BIO icon

Samlyn Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Samlyn Capital’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-97,633
Closed -$28.2M – 129
2018
Q2 		$28.2M Sell
97,633
-81,167
-45% -$22.4M 0.66% 56
2018
Q1 		$44.7M Sell
178,800
-40,519
-18% -$10.3M 0.98% 36
2017
Q4 		$52.3M Buy
219,319
+104,335
+91% +$25.3M 1.2% 32
2017
Q3 		$25.6M Buy
+114,984
New +$25.9M 0.65% 54

Other funds holding BIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Samlyn Capital's BIO Position: Q3 2018 in Review

Samlyn Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2018, closing a stake of 97,633 shares — an estimated $28.2M sold.

Samlyn Capital first reported a position in BIO in Q3 2017 and held it in 4 quarters. The position peaked at $52.3M in Q4 2017. 343 funds tracked by Wall St. Rank hold BIO as of Q3 2018.

  • Samlyn Capital reported no remaining Bio-Rad Laboratories Class A position as of Q3 2018 after selling out during the quarter.
  • Samlyn Capital sold 97,633 Bio-Rad Laboratories Class A shares in Q3 2018, an estimated $28.2M.
  • Samlyn Capital first reported a position in Bio-Rad Laboratories Class A in Q3 2017 and held it in 4 quarters.
  • Samlyn Capital's Bio-Rad Laboratories Class A position peaked at $52.3M in Q4 2017.
  • 343 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2018.

Based on Samlyn Capital's 13F filing for Q3 2018, filed 14 Nov 2018.